Topic summary

What would change my mind about repair peptides: a specific answer — one year on

Compounds › Repair & healing peptides needs a source observational data TB-500 preprint Closed

This is a generated summary. It shows the 5 most-liked posts from a topic of 14, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

cannula_traceTL3Regular3 Oct 2024#1

What would change my mind about repair peptides: a specific answer — one year on I have a specific reason for asking rather than idle curiosity, and the context is below.

Session topic: STEP 1 (N Engl J Med, 2021). Please read it before posting; the discussion is much better when everyone has.

The question I would like us to start with is what the trial set out to estimate, rather than what it found. Once that is on the table we can talk about whether the design could have answered it, and only then about the numbers.

Specific things I would like covered: the population and how far it generalises, how discontinuation was handled, whether the comparator was a fair one, and what the absolute rather than relative effect looks like.

I will summarise at the end and the summary will feed the relevant digest page.

54 likes 22mo

l.lundgrenTL2 Moderator14 Oct 2024#2

the opening post answers the question as asked. The question underneath it is different.

The absence of adequately powered published randomised human trials is the central fact about BPC-157. This site states that plainly rather than hedging. Mechanistic plausibility does not substitute for it.

14 likes 21mo

m.amankwahTL2 Moderator11 Nov 2024#6

NLoughran, post #5: Worth separating two things that the opening post runs together. Publication patterns in the BPC-157 literature: a large proportion of the evidence comes from one research group. That is not necessarily wrong — one group can do excellent work — but it is worth noting when evaluating the breadth of support for a claim. Go to post

post #5 is right about the mechanism and I think understates the practical bit.

Stability of BPC-157 in solution: what has been measured in published work covers specific formulations under specific conditions. Extrapolating to a reconstituted preparation in a different diluent at a different concentration is an extrapolation, acknowledged as one.

20 likes in reply to #5 21mo

ThibodeauTL3Regular28 Nov 2024#9

cannula_trace, post #1: What would change my mind about repair peptides: a specific answer — one year on I have a specific reason for asking rather than idle curiosity, and the context is below. Session topic: STEP 1 ( N Engl J Med , 2021). Please read it before posting; the discussion is much better when everyone has. The question I would like us to start… Go to post

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

15 likes in reply to #1 20mo

s.vukovicTL2 Moderator23 Dec 2024#14

I read post #12 twice before replying, because I had assumed the opposite.

The distinction between "no evidence it works" and "evidence it does not work": we have the first for these compounds. That is genuinely different from the second and the distinction matters, but it also means treatment plans based on these compounds are being built on theoretical grounds, not empirical ones.

20 likes 19mo

Read the full topic (14 posts)

This topic was referenced in

Publication patterns in the BPC-157 literature, examinedCompounds › Repair & healing peptides · 45 replies

This topic was closed 180 days after the last reply. Closing is automatic for quiet topics so that a settled answer does not collect new questions underneath it. If you have a follow-up, open a new topic and link back to this one — that keeps both readable and gives your question its own title.

Suggested topics

Topic	Participants	Replies	Views	Activity
Stability of BPC-157 in solution: what has been measured — one year on Compounds › Repair & healing peptides needs a source observational data preprint BPC-157 On the subject in the title: Stability of BPC-157 in solution: what has been measured — one year on Working notes rather than a conclusion. Comparing STEP 2 ( Lancet , 2021) with STEP 1 ( N Engl J Med , 2021)…	+84	98	7.8k	18h
Analytical identity of BPC-157: a 15-mer with a simple mass — does this still hold? Compounds › Repair & healing peptides needs a source preprint BPC-157 Analytical identity of BPC-157: a 15-mer with a simple mass — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURPASS-2 ( N Engl J…	+28	33	1.6k	1mo
BPC-157: what the rodent literature actually shows, and what it does not — a second dataset Compounds › Repair & healing peptides TB-500 preprint observational data needs a source Solved On the subject in the title: BPC-157: what the rodent literature actually shows, and what it does not — a second dataset Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019)…	+77	84	54k	11mo
[2026 update] Publication patterns in the BPC-157 literature, examined Compounds › Repair & healing peptides BPC-157 observational data TB-500 Solved Publication patterns in the BPC-157 literature, examined Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURMOUNT-OSA ( N Engl J Med , 2024). Please read it…	+15	19	11k	4mo
Revisiting: Why the absence of controlled human data on BPC-157 matters more than people admit Compounds › Repair & healing peptides observational data TB-500 BPC-157 preprint Solved Revisiting: Why the absence of controlled human data on BPC-157 matters more than people admit Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURPASS-4 ( Lancet ,…	+50	55	7.8k	2d

Related topics — sharing the tags needs a source, observational data, TB-500

Topic	Participants	Replies	Views	Activity
How to research a compound with no human data without deceiving yourself Compounds › Other compounds needs a source mislabelling custom synthesis research use only Solved Asking directly, because I could not find a straight answer: How to research a compound with no human data without deceiving yourself Session topic: STEP 2 ( Lancet , 2021). Please read it before posting; the…	+107	119	11k	12mo
Follow-up: The retatrutide phase 2 obesity paper, read closely Compounds › Retatrutide retatrutide randomised trial preprint effect size The retatrutide phase 2 obesity paper, read closely — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support of a claim I do not think it…	+19	23	16k	2d
What a well-designed human trial of a secretagogue would look like Compounds › Secretagogues & GH axis GHRP class ipamorelin CJC-1295 tesamorelin Solved What a well-designed human trial of a secretagogue would look like I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited…		2	7.2k	18mo
Secretagogues and glucose tolerance: the mechanistic concern Compounds › Secretagogues & GH axis CJC-1295 tesamorelin observational data needs a source On the subject in the title: Secretagogues and glucose tolerance: the mechanistic concern Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…	+64	70	52k	17d
Why retatrutide discussion here is more cautious than elsewhere Compounds › Retatrutide randomised trial effect size retatrutide preprint Solved Why retatrutide discussion here is more cautious than elsewhere I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURMOUNT-OSA ( N Engl J Med , 2024) cited…	+7	12	7.7k	2mo